Condition: Primary Mediastinal B Cell Lymphoma · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed/Refractory
This description comes directly from the study's public registry record.
Pier Luigi Zinzani, MD · +390512144042 · pierluigi.zinzani@unibo.it
Cinzia Pellegrini, MD · +390512143680 · cinzia.pellegrini@aosp.bo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero - Universitaria di Bologna | Bologna, Bologna, Italy | Recruiting |
| Azienda Ospedaliera Universitaria- POLICLINICO BARI | Bari, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06781450